Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Infanrix hexa
Infanrix-Hexa · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Infanrix-Hexa | BIOLOGICAL | - |
Inclusion Criteria: * A male or female infant at the age of 11 - 17 weeks. * Written informed consent obtained from the parents or guardians of the subject. * Free of obvious health problems as established by clinical examination before entering into the study. * Hepatitis B vaccine at birth and on...
Infanrix hexa is a vaccine used to protect against tetanus, acellular pertussis, streptococcal infections, poliomyelitis, and hepatitis B. It is administered to infants to provide immunity against these infectious diseases. The vaccine is developed by GSK plc and is currently in Phase 3 clinical development.
Infanrix hexa is developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in infants.
Infanrix hexa is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. GSK plc is conducting multiple Phase 3 trials to assess its safety and effectiveness in preventing infectious diseases.
Infanrix hexa has been studied in several completed clinical trials, including NCT00366366, NCT01248884, NCT01353703, and NCT02096263. These trials evaluated the vaccine's immunogenicity and safety in infants across different countries, with a total enrollment of 1,597 participants.
Infanrix hexa is a vaccine that works by stimulating the immune system to produce antibodies against the antigens for tetanus, acellular pertussis, streptococcal infections, poliomyelitis, and hepatitis B. This helps protect infants from these infectious diseases.
Infanrix hexa is also known as the DTPa-HBV-IPV/Hib vaccine, which combines diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b antigens. Clinical trials refer to it by this alternative name.